Last reviewed · How we verify
BRY812 for injection
BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor.
BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | BRY812 for injection |
|---|---|
| Sponsor | BioRay Pharmaceutical Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, BRY812 for injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This mechanism is thought to be responsible for the therapeutic effects of BRY812 for injection in the treatment of various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies (PHASE2)
- A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRY812 for injection CI brief — competitive landscape report
- BRY812 for injection updates RSS · CI watch RSS
- BioRay Pharmaceutical Co., Ltd. portfolio CI